ID   UPPS_ECOLI              Reviewed;         253 AA.
AC   P60472; P75668; Q47675; Q9R2E4;
DT   16-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   16-FEB-2004, sequence version 1.
DT   15-MAR-2017, entry version 121.
DE   RecName: Full=Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific);
DE            EC=2.5.1.31;
DE   AltName: Full=Ditrans,polycis-undecaprenylcistransferase;
DE   AltName: Full=Undecaprenyl diphosphate synthase;
DE            Short=UDS;
DE   AltName: Full=Undecaprenyl pyrophosphate synthase;
DE            Short=UPP synthase;
GN   Name=ispU; Synonyms=rth, uppS, yaeS; OrderedLocusNames=b0174, JW0169;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RA   Takemoto K., Mori H., Murayama N., Kataoka K., Yano M., Itoh T.,
RA   Yamamoto Y., Inokuchi H., Miki T., Hatada E., Fukuda R., Ichihara S.,
RA   Mizuno T., Makino K., Nakata A., Yura T., Sampei G., Mizobuchi K.;
RT   "Systematic sequencing of the Escherichia coli genome: analysis of the
RT   4.0 - 6.0 min (189,987 - 281,416bp) region.";
RL   Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RA   Chung E., Allen E., Araujo R., Aparicio A.M., Davis K., Duncan M.,
RA   Federspiel N., Hyman R., Kalman S., Komp C., Kurdi O., Lew H., Lin D.,
RA   Namath A., Oefner P., Roberts D., Schramm S., Davis R.W.;
RT   "Sequence of minutes 4-25 of Escherichia coli.";
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1462(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [5]
RP   CHARACTERIZATION.
RX   PubMed=9882662;
RA   Apfel C.M., Takacs B., Fountoulakis M., Stieger M., Keck W.;
RT   "Use of genomics to identify bacterial undecaprenyl pyrophosphate
RT   synthetase: cloning, expression, and characterization of the essential
RT   uppS gene.";
RL   J. Bacteriol. 181:483-492(1999).
RN   [6]
RP   CHARACTERIZATION.
RX   PubMed=10217761;
RA   Kato J., Fujisaki S., Nakajima K., Nishimura Y., Sato M., Nakano A.;
RT   "The Escherichia coli homologue of yeast RER2, a key enzyme of
RT   dolichol synthesis, is essential for carrier lipid formation in
RT   bacterial cell wall synthesis.";
RL   J. Bacteriol. 181:2733-2738(1999).
RN   [7]
RP   MUTAGENESIS OF ASP-26; GLU-73; ASP-150; ASP-190; GLU-198; GLU-213;
RP   ASP-218 AND ASP-223.
RX   PubMed=11076526; DOI=10.1021/bi001226h;
RA   Pan J.-J., Yang L.-W., Liang P.-H.;
RT   "Effect of site-directed mutagenesis of the conserved aspartate and
RT   glutamate on E. coli undecaprenyl pyrophosphate synthase catalysis.";
RL   Biochemistry 39:13856-13861(2000).
RN   [8]
RP   MUTAGENESIS OF TRP-31; TRP-75; TRP-91; TRP-149; TRP-207 AND TRP-221.
RX   PubMed=11744728; DOI=10.1074/jbc.M110014200;
RA   Chen Y.-H., Chen A.P.-C., Chen C.-T., Wang A.H.-J., Liang P.-H.;
RT   "Probing the conformational change of Escherichia coli undecaprenyl
RT   pyrophosphate synthase during catalysis using an inhibitor and
RT   tryptophan mutants.";
RL   J. Biol. Chem. 277:7369-7376(2002).
RN   [9]
RP   REACTION MECHASNISM.
RX   PubMed=20828539; DOI=10.1016/j.bbrc.2010.09.001;
RA   Lu Y.P., Liu H.G., Teng K.H., Liang P.H.;
RT   "Mechanism of cis-prenyltransferase reaction probed by substrate
RT   analogues.";
RL   Biochem. Biophys. Res. Commun. 400:758-762(2010).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 13-240, MUTAGENESIS OF
RP   ILE-62; ALA-69; SER-71; GLU-73; ASN-74; TRP-75; ARG-77; GLU-81;
RP   HIS-103; VAL-105; LEU-137 AND ALA-143, AND SUBUNIT.
RX   PubMed=11581264; DOI=10.1074/jbc.M106747200;
RA   Ko T.-P., Chen Y.-K., Robinson H., Tsai P.-C., Gao Y.-G.,
RA   Chen A.P.-C., Wang A.H.-J., Liang P.-H.;
RT   "Mechanism of product chain length determination and the role of a
RT   flexible loop in Escherichia coli undecaprenyl-pyrophosphate synthase
RT   catalysis.";
RL   J. Biol. Chem. 276:47474-47482(2001).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.73 ANGSTROMS) OF 13-240 IN COMPLEX WITH
RP   SUBSTRATES ANALOGS AND MAGNESIUM IONS, FUNCTION AS AN UNDECAPRENYL
RP   DIPHOSPHATE SYNTHASE, MUTAGENESIS OF HIS-43; HIS-199 AND GLU-213,
RP   BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR, AND SUBUNIT.
RX   PubMed=12756244; DOI=10.1074/jbc.M302687200;
RA   Chang S.-Y., Ko T.-P., Liang P.-H., Wang A.H.-J.;
RT   "Catalytic mechanism revealed by the crystal structure of undecaprenyl
RT   pyrophosphate synthase in complex with sulfate, magnesium, and
RT   triton.";
RL   J. Biol. Chem. 278:29298-29307(2003).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) IN COMPLEX WITH SUBSTRATE,
RP   COFACTOR, AND SUBUNIT.
RX   PubMed=15044730; DOI=10.1110/ps.03519904;
RA   Chang S.Y., Ko T.P., Chen A.P., Wang A.H., Liang P.H.;
RT   "Substrate binding mode and reaction mechanism of undecaprenyl
RT   pyrophosphate synthase deduced from crystallographic studies.";
RL   Protein Sci. 13:971-978(2004).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF WILD-TYPE AND OF MUTANT
RP   ALA-26 IN COMPLEX WITH SUBSTRATE ANALOGS AND MAGNESIUM IONS.
RX   PubMed=15788389; DOI=10.1074/jbc.M502121200;
RA   Guo R.T., Ko T.P., Chen A.P., Kuo C.J., Wang A.H., Liang P.H.;
RT   "Crystal structures of undecaprenyl pyrophosphate synthase in complex
RT   with magnesium, isopentenyl pyrophosphate, and farnesyl
RT   thiopyrophosphate: roles of the metal ion and conserved residues in
RT   catalysis.";
RL   J. Biol. Chem. 280:20762-20774(2005).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) IN COMPLEX WITH SUBSTRATE
RP   ANALOGS, ENZYME REGULATION, AND SUBUNIT.
RX   PubMed=17535895; DOI=10.1073/pnas.0702254104;
RA   Guo R.-T., Cao R., Liang P.-H., Ko T.-P., Chang T.-H., Hudock M.P.,
RA   Jeng W.-Y., Chen C.K.-M., Zhang Y., Song Y., Kuo C.-J., Yin F.,
RA   Oldfield E., Wang A.H.-J.;
RT   "Bisphosphonates target multiple sites in both cis- and trans-
RT   prenyltransferases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:10022-10027(2007).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS), AND SUBUNIT.
RX   PubMed=21294851; DOI=10.1111/j.1747-0285.2011.01101.x;
RA   Sinko W., de Oliveira C., Williams S., Van Wynsberghe A.,
RA   Durrant J.D., Cao R., Oldfield E., McCammon J.A.;
RT   "Applying molecular dynamics simulations to identify rarely sampled
RT   ligand-bound conformational states of undecaprenyl pyrophosphate
RT   synthase, an antibacterial target.";
RL   Chem. Biol. Drug Des. 77:412-420(2011).
CC   -!- FUNCTION: Generates ditrans,octacis-undecaprenyl pyrophosphate
CC       (UPP) from isopentenyl pyrophosphate (IPP) and farnesyl
CC       diphosphate (FPP). UPP is the precursor of glycosyl carrier lipid
CC       in the biosynthesis of bacterial cell wall polysaccharide
CC       components such as peptidoglycan and lipopolysaccharide.
CC       {ECO:0000269|PubMed:12756244}.
CC   -!- CATALYTIC ACTIVITY: (2E,6E)-farnesyl diphosphate + 8 isopentenyl
CC       diphosphate = 8 diphosphate + di-trans,octa-cis-undecaprenyl
CC       diphosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:12756244,
CC         ECO:0000269|PubMed:15044730};
CC       Note=Binds 2 magnesium ions per subunit.
CC       {ECO:0000269|PubMed:12756244, ECO:0000269|PubMed:15044730};
CC   -!- ENZYME REGULATION: Inhibited by bisphosphonates.
CC       {ECO:0000269|PubMed:17535895}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.4 uM for FPP (at pH 7.5 and at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:12756244};
CC         KM=4.1 uM for IPP (at pH 7.5 and at 25 degrees Celsius)
CC         {ECO:0000269|PubMed:12756244};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:11581264,
CC       ECO:0000269|PubMed:12756244, ECO:0000269|PubMed:15044730,
CC       ECO:0000269|PubMed:15788389, ECO:0000269|PubMed:17535895,
CC       ECO:0000269|PubMed:21294851}.
CC   -!- SIMILARITY: Belongs to the UPP synthase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB08603.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U70214; AAB08603.1; ALT_INIT; Genomic_DNA.
DR   EMBL; U00096; AAC73285.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAA77849.2; -; Genomic_DNA.
DR   PIR; F64741; F64741.
DR   RefSeq; NP_414716.1; NC_000913.3.
DR   PDB; 1JP3; X-ray; 1.80 A; A/B=1-253.
DR   PDB; 1UEH; X-ray; 1.73 A; A/B=1-253.
DR   PDB; 1V7U; X-ray; 2.35 A; A/B=1-253.
DR   PDB; 1X06; X-ray; 1.90 A; A=1-253.
DR   PDB; 1X07; X-ray; 2.20 A; A=1-253.
DR   PDB; 1X08; X-ray; 1.90 A; A=1-253.
DR   PDB; 1X09; X-ray; 1.87 A; A=1-253.
DR   PDB; 2E98; X-ray; 1.90 A; A/B=1-253.
DR   PDB; 2E99; X-ray; 2.00 A; A/B=1-253.
DR   PDB; 2E9A; X-ray; 2.10 A; A/B=1-253.
DR   PDB; 2E9C; X-ray; 2.05 A; A/B=1-253.
DR   PDB; 2E9D; X-ray; 2.50 A; A/B=1-253.
DR   PDB; 3QAS; X-ray; 1.70 A; A/B=1-253.
DR   PDB; 3SGV; X-ray; 1.61 A; A/B=1-253.
DR   PDB; 3SGX; X-ray; 2.45 A; A/B=1-253.
DR   PDB; 3SH0; X-ray; 1.84 A; A/B=1-253.
DR   PDB; 3TH8; X-ray; 2.11 A; A/B=1-253.
DR   PDB; 3WYJ; X-ray; 2.10 A; A/B=1-253.
DR   PDB; 4H2J; X-ray; 1.81 A; A/B=1-253.
DR   PDB; 4H2M; X-ray; 1.78 A; A/B=1-253.
DR   PDB; 4H2O; X-ray; 2.14 A; A/B=1-253.
DR   PDB; 4H38; X-ray; 1.95 A; A/B=1-253.
DR   PDB; 4H3A; X-ray; 1.98 A; A/B=1-253.
DR   PDB; 4H3C; X-ray; 1.93 A; A/B=1-253.
DR   PDB; 5CQB; X-ray; 2.20 A; A/B=2-253.
DR   PDB; 5CQJ; X-ray; 2.15 A; A/B=1-253.
DR   PDBsum; 1JP3; -.
DR   PDBsum; 1UEH; -.
DR   PDBsum; 1V7U; -.
DR   PDBsum; 1X06; -.
DR   PDBsum; 1X07; -.
DR   PDBsum; 1X08; -.
DR   PDBsum; 1X09; -.
DR   PDBsum; 2E98; -.
DR   PDBsum; 2E99; -.
DR   PDBsum; 2E9A; -.
DR   PDBsum; 2E9C; -.
DR   PDBsum; 2E9D; -.
DR   PDBsum; 3QAS; -.
DR   PDBsum; 3SGV; -.
DR   PDBsum; 3SGX; -.
DR   PDBsum; 3SH0; -.
DR   PDBsum; 3TH8; -.
DR   PDBsum; 3WYJ; -.
DR   PDBsum; 4H2J; -.
DR   PDBsum; 4H2M; -.
DR   PDBsum; 4H2O; -.
DR   PDBsum; 4H38; -.
DR   PDBsum; 4H3A; -.
DR   PDBsum; 4H3C; -.
DR   PDBsum; 5CQB; -.
DR   PDBsum; 5CQJ; -.
DR   DisProt; DP00516; -.
DR   ProteinModelPortal; P60472; -.
DR   SMR; P60472; -.
DR   BioGrid; 4260767; 393.
DR   DIP; DIP-48251N; -.
DR   IntAct; P60472; 4.
DR   STRING; 511145.b0174; -.
DR   DrugBank; DB07410; [2-(3-DIBENZOFURAN-4-YL-PHENYL)-1-HYDROXY-1-PHOSPHONO-ETHYL]-PHOSPHONIC ACID.
DR   DrugBank; DB07780; FARNESYL DIPHOSPHATE.
DR   DrugBank; DB04695; FARNESYL THIOPYROPHOSPHATE.
DR   DrugBank; DB04714; ISOPENTENYL PYROPHOSPHATE.
DR   PaxDb; P60472; -.
DR   PRIDE; P60472; -.
DR   EnsemblBacteria; AAC73285; AAC73285; b0174.
DR   EnsemblBacteria; BAA77849; BAA77849; BAA77849.
DR   GeneID; 944874; -.
DR   KEGG; ecj:JW0169; -.
DR   KEGG; eco:b0174; -.
DR   PATRIC; 32115457; VBIEscCol129921_0180.
DR   EchoBASE; EB3113; -.
DR   EcoGene; EG13329; ispU.
DR   eggNOG; ENOG4105CR3; Bacteria.
DR   eggNOG; COG0020; LUCA.
DR   HOGENOM; HOG000006054; -.
DR   InParanoid; P60472; -.
DR   KO; K00806; -.
DR   OMA; WAKLKNK; -.
DR   PhylomeDB; P60472; -.
DR   BioCyc; EcoCyc:UPPSYN-MONOMER; -.
DR   BioCyc; MetaCyc:UPPSYN-MONOMER; -.
DR   BRENDA; 2.5.1.31; 2026.
DR   EvolutionaryTrace; P60472; -.
DR   PRO; PR:P60472; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IDA:EcoCyc.
DR   GO; GO:0005829; C:cytosol; IDA:EcoCyc.
DR   GO; GO:0008834; F:di-trans,poly-cis-decaprenylcistransferase activity; IDA:EcoCyc.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:EcoCyc.
DR   GO; GO:0002094; F:polyprenyltransferase activity; IBA:GO_Central.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0071555; P:cell wall organization; IEA:UniProtKB-KW.
DR   GO; GO:0043164; P:Gram-negative-bacterium-type cell wall biogenesis; IMP:EcoCyc.
DR   GO; GO:0009252; P:peptidoglycan biosynthetic process; IMP:EcoCyc.
DR   GO; GO:0016094; P:polyprenol biosynthetic process; IDA:EcoCyc.
DR   GO; GO:0008360; P:regulation of cell shape; IEA:UniProtKB-KW.
DR   CDD; cd00475; Cis_IPPS; 1.
DR   Gene3D; 3.40.1180.10; -; 1.
DR   HAMAP; MF_01139; ISPT; 1.
DR   InterPro; IPR001441; UPP_synth-like.
DR   InterPro; IPR018520; UPP_synth-like_CS.
DR   PANTHER; PTHR10291; PTHR10291; 1.
DR   Pfam; PF01255; Prenyltransf; 1.
DR   SUPFAM; SSF64005; SSF64005; 1.
DR   TIGRFAMs; TIGR00055; uppS; 1.
DR   PROSITE; PS01066; UPP_SYNTHASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell cycle; Cell division; Cell shape;
KW   Cell wall biogenesis/degradation; Complete proteome; Magnesium;
KW   Metal-binding; Peptidoglycan synthesis; Reference proteome;
KW   Transferase.
FT   CHAIN         1    253       Ditrans,polycis-undecaprenyl-diphosphate
FT                                synthase ((2E,6E)-farnesyl-diphosphate
FT                                specific).
FT                                /FTId=PRO_0000123609.
FT   REGION       26     30       Substrate binding.
FT   REGION       71     73       Substrate binding. {ECO:0000250}.
FT   REGION      200    202       Substrate binding.
FT   ACT_SITE     26     26
FT   ACT_SITE     74     74       Proton acceptor. {ECO:0000250}.
FT   METAL        26     26       Magnesium.
FT   METAL       199    199       Magnesium.
FT   METAL       213    213       Magnesium.
FT   BINDING      31     31       Substrate. {ECO:0000305|PubMed:15044730}.
FT   BINDING      39     39       Substrate. {ECO:0000269|PubMed:15044730}.
FT   BINDING      43     43       Substrate. {ECO:0000269|PubMed:15044730}.
FT   BINDING      75     75       Substrate. {ECO:0000305|PubMed:15044730}.
FT   BINDING      77     77       Substrate. {ECO:0000269|PubMed:15044730}.
FT   BINDING     194    194       Substrate. {ECO:0000269|PubMed:15044730}.
FT   BINDING     213    213       Isopentenyl diphosphate.
FT   SITE         69     69       Required for continued chain elongation.
FT   SITE        137    137       Important for determining product length.
FT   MUTAGEN      26     26       D->A: Great decrease in activity.
FT                                {ECO:0000269|PubMed:11076526}.
FT   MUTAGEN      31     31       W->F: Decrease in activity; reduced
FT                                affinity for decaprenyl diphosphate
FT                                substrate analog.
FT                                {ECO:0000269|PubMed:11744728}.
FT   MUTAGEN      43     43       H->A: Great decreases in the catalytic
FT                                efficiency and the affinity for FPP and
FT                                IPP. {ECO:0000269|PubMed:12756244}.
FT   MUTAGEN      62     62       I->A: Formation predominantly of C(60)
FT                                and C(65) polymers rather than the C(55)
FT                                polymer. {ECO:0000269|PubMed:11581264}.
FT   MUTAGEN      69     69       A->L: Produces shorter polymers.
FT                                {ECO:0000269|PubMed:11581264}.
FT   MUTAGEN      71     71       S->A: Decrease in activity.
FT                                {ECO:0000269|PubMed:11581264}.
FT   MUTAGEN      73     73       E->A: Slight decrease in activity.
FT                                {ECO:0000269|PubMed:11076526,
FT                                ECO:0000269|PubMed:11581264}.
FT   MUTAGEN      74     74       N->A: Decrease in activity.
FT                                {ECO:0000269|PubMed:11581264}.
FT   MUTAGEN      75     75       W->A,F: Decrease in activity; reduced
FT                                affinity for decaprenyl diphosphate
FT                                substrate analog.
FT                                {ECO:0000269|PubMed:11581264,
FT                                ECO:0000269|PubMed:11744728}.
FT   MUTAGEN      77     77       R->A: Decrease in activity.
FT                                {ECO:0000269|PubMed:11581264}.
FT   MUTAGEN      81     81       E->A: Slight decrease in activity.
FT                                {ECO:0000269|PubMed:11581264}.
FT   MUTAGEN      91     91       W->F: Decrease in affinity for IPP.
FT                                {ECO:0000269|PubMed:11744728}.
FT   MUTAGEN     103    103       H->A: No effect.
FT                                {ECO:0000269|PubMed:11581264}.
FT   MUTAGEN     105    105       V->A: Formation predominantly of C(60),
FT                                C(65) and C(70) polymers rather than the
FT                                C(55) polymer.
FT                                {ECO:0000269|PubMed:11581264}.
FT   MUTAGEN     137    137       L->A: Formation predominantly of a C(70)
FT                                polymer rather than the C(55) polymer.
FT                                {ECO:0000269|PubMed:11581264}.
FT   MUTAGEN     143    143       A->V: No effect on polymer length.
FT                                {ECO:0000269|PubMed:11581264}.
FT   MUTAGEN     149    149       W->F: Decrease in affinity for IPP.
FT                                {ECO:0000269|PubMed:11744728}.
FT   MUTAGEN     150    150       D->A: Great decrease in affinity for the
FT                                substrate. {ECO:0000269|PubMed:11076526}.
FT   MUTAGEN     190    190       D->A: No effect.
FT                                {ECO:0000269|PubMed:11076526}.
FT   MUTAGEN     198    198       E->A: No effect.
FT                                {ECO:0000269|PubMed:11076526}.
FT   MUTAGEN     199    199       H->A: Great decreases in the catalytic
FT                                efficiency and in the affinity for IPP;
FT                                when associated with A-213.
FT                                {ECO:0000269|PubMed:12756244}.
FT   MUTAGEN     207    207       W->F: Decrease in affinity for both IPP
FT                                and decaprenyl diphosphate substrate
FT                                analog. {ECO:0000269|PubMed:11744728}.
FT   MUTAGEN     213    213       E->A: Great decrease in activity; reduced
FT                                affinity for IPP. Great decreases in the
FT                                catalytic efficiency and in the affinity
FT                                for IPP; when associated with A-199.
FT                                {ECO:0000269|PubMed:11076526,
FT                                ECO:0000269|PubMed:12756244}.
FT   MUTAGEN     218    218       D->A: Slight decrease in activity.
FT                                {ECO:0000269|PubMed:11076526}.
FT   MUTAGEN     221    221       W->F: Decrease in affinity for IPP.
FT                                {ECO:0000269|PubMed:11744728}.
FT   MUTAGEN     223    223       D->A: No effect.
FT                                {ECO:0000269|PubMed:11076526}.
FT   HELIX        15     17       {ECO:0000244|PDB:1X09}.
FT   STRAND       19     25       {ECO:0000244|PDB:3SGV}.
FT   HELIX        28     34       {ECO:0000244|PDB:3SGV}.
FT   HELIX        39     59       {ECO:0000244|PDB:3SGV}.
FT   STRAND       63     68       {ECO:0000244|PDB:3SGV}.
FT   HELIX        72     75       {ECO:0000244|PDB:3SGV}.
FT   HELIX        83     90       {ECO:0000244|PDB:3SGV}.
FT   HELIX        93    102       {ECO:0000244|PDB:3SGV}.
FT   STRAND      106    111       {ECO:0000244|PDB:3SGV}.
FT   HELIX       113    115       {ECO:0000244|PDB:3SGV}.
FT   HELIX       118    131       {ECO:0000244|PDB:3SGV}.
FT   STRAND      138    144       {ECO:0000244|PDB:3SGV}.
FT   HELIX       147    164       {ECO:0000244|PDB:3SGV}.
FT   HELIX       169    171       {ECO:0000244|PDB:3SGV}.
FT   HELIX       174    178       {ECO:0000244|PDB:3SGV}.
FT   TURN        182    185       {ECO:0000244|PDB:3SGV}.
FT   STRAND      191    197       {ECO:0000244|PDB:3SGV}.
FT   STRAND      204    206       {ECO:0000244|PDB:3WYJ}.
FT   HELIX       207    209       {ECO:0000244|PDB:3SGV}.
FT   STRAND      213    216       {ECO:0000244|PDB:3SGV}.
FT   HELIX       221    223       {ECO:0000244|PDB:3SGV}.
FT   HELIX       226    239       {ECO:0000244|PDB:3SGV}.
SQ   SEQUENCE   253 AA;  28444 MW;  73DC9534C14CA7B9 CRC64;
     MMLSATQPLS EKLPAHGCRH VAIIMDGNGR WAKKQGKIRA FGHKAGAKSV RRAVSFAANN
     GIEALTLYAF SSENWNRPAQ EVSALMELFV WALDSEVKSL HRHNVRLRII GDTSRFNSRL
     QERIRKSEAL TAGNTGLTLN IAANYGGRWD IVQGVRQLAE KVQQGNLQPD QIDEEMLNQH
     VCMHELAPVD LVIRTGGEHR ISNFLLWQIA YAELYFTDVL WPDFDEQDFE GALNAFANRE
     RRFGGTEPGD ETA
//
